Overcoming Treatment Resistance in High Grade Gliomas
- Author:
Chae Yong KIM
1
;
Young Hoon KIM
Author Information
1. Department of Neurosurgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. chaeyong@snu.ac.kr
- Publication Type:Review
- Keywords:
Glioma;
Temozolomide;
MGMT;
Radiotherapy
- MeSH:
Astrocytoma;
Dacarbazine;
Glioblastoma;
Glioma;
Humans;
Nervous System;
Oligodendroglioma;
Prognosis
- From:Clinical Pediatric Hematology-Oncology
2012;19(1):7-16
- CountryRepublic of Korea
- Language:English
-
Abstract:
Malignant gliomas, including glioblastomas, anaplastic astrocytomas and anaplastic oligodendrogliomas, are the most common primary neoplasm of the human nervous system. Although the results of radiotherapy and chemotherapy such as temozolomide have improved the prognosis of patient with high grade gliomas, generally the outcomes are still miserable due to the resistance to current therapies. Therefore, recent trials and researches have focused on overcoming the resistance to standard chemo- and radiotherapy of malignant gliomas and are demonstrating the outstanding results. In the present review, we provide an overview of current status of the conventional therapies for malignant gliomas and recent advances for overcoming the resistance to the therapies.
